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Robert J. Myerburg, MDV ariations in clinical expression of geneticallybased disorders are common, especially forsyndromes characterized by complex physi-
ological pathways. Although not unique to the
inherited long QT syndromes (LQTS), patterns of
complex interactions are particularly striking in fam-
ilies in which multiple relatives carry an LQT variant
identiﬁed in a proband (1–3), creating challenges for
clinicians, electrophysiologists, and clinical geneti-
cists. Variations in expression of both the presence
and extent of QT prolongation (Figure 1, Level 1) as
well as clinical events (Figure 1, Level 2) (4) manifest
among carriers of LQTS mutations in large family
cohorts. Because a major goal of genetic testing is
risk identiﬁcation and proﬁling of relatives of pro-
bands, it follows that variable expression limits clin-
ical decision making in asymptomatic carriers.
Investigators have long sought identiﬁable modi-
ﬁers of risk in individual LQTS carriers. The vague
and physiologically imprecise notion of “incomplete
penetrance” was the ﬁrst explanation of this phe-
nomenon, but that idea generated only hypothetical
pathways. The concept of “modiﬁer genes” for LQTS
expression emerged early after the discovery of the
primary variants associated with LQTS. The theory:
single-nucleotide polymorphisms or mutations that
were clinically unimportant alone interacted with
disease-causing mutations to alter expression of the*Editorials published in the Journal of the American College of Cardiology
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disclose.primary defect. Even though LQTS risk modiﬁers that
may enhance (5) or decrease (6) intensity of expres-
sion have been reported, progress has been slow, in
part because expression is also modulated by various
physiological ﬂuctuations, drug and electrolyte in-
ﬂuences, and environmental factors. For example,
very early in the development of insights into LQTS,
the role of sympathetic nervous system activity in
expression modulation became evident, leading to
left stellate ganglionectomy as the ﬁrst effective
therapy in 1971 (7), subsequently followed by beta-
blocker therapy when that class of drugs became
available.
Other factors modifying clinical expression,
derived from physiology, pharmacology, and elec-
trolyte balance, continued to emerge, with physicians
becoming familiar with interactions with drugs that
inﬂuence cardiac repolarizing currents, serum potas-
sium and magnesium levels, and permissible in-
tensity of exercise. Drug exposures and serum
electrolyte variations can interact with defective ion
channel control of membrane currents in patients
with LQTS. For instance, although severe hypokale-
mia alone can lengthen the QT interval sufﬁciently
to cause ventricular arrhythmias, lesser degrees of
hypokalemia or even low normal serum potassium
levels can elicit such effects when associated with
an inherited blunting of transmembrane potassium
currents. The basis for this phenomenon lies in the
general relationship between low extracellular
potassium levels and reduced current density in some
potassium channel species (8).SEE PAGE 367Against this background of possible molecular and
physiological interactions with LQTS-causing muta-
tions, the use of the term “genetic modiﬁcation” is
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Clinical expression of long QT syndrome (LQTS) can be viewed as a multistage expression algorithm. Level 1 in gene-positive subjects refers to
whether and what extent the corrected QT interval (QTc) lengthens. Level 2 refers to expression variability of clinical events, based upon
physiological, environmental, and genetic modiﬁers. This feature of LQTS reﬂects the difﬁculty in decision making in gene-positive carriers, with
and without baseline QTc prolongation. Modiﬁed with permission from Myerburg and Castellanos (4).
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376suggested as a generalization with dual implications:
1) alteration of primary genetic effects on ion chan-
nels by interaction with a second genetic variant; and
2) modiﬁcation of the expression of a disease-causing
mutation by nongenetic factors inﬂuencing its
pathway of expression. The report by Porta et al. (9)
in this issue of the Journal integrates both of these
implications: the general sympathetic inﬂuence on
expression in LQTS type 1 (LQT1) paired with the
possibility of genetic inﬂuences affecting responses
to a physiological modiﬁer of expression. The
extraordinarily well-studied South African founder
genotype (KCNQ1 A341V), characterized by an epide-
miologically and clinically powerful phenotype, was
examined to evaluate the role of sympathetic activity
in modifying risk in this LQT1 population because
LQT1 is particularly sensitive to sympathetic activity.
Nearly 80% of A341V carriers become symptomatic by
40 years of age, compared with approximately 30%
among other KCNQ1 variants (10,11). The researchers
previously reported that asymptomatic mutation
carriers (AMCs) of LQT1 variants are more likely to
have lower heart rates, lower baroreceptor sensi-
tivity, and a lesser degree of heart rate decrease at the
end of exercise than symptomatic mutation carriers
(SMCs). These data suggest a protective effect of
reduced vagal reﬂexes but do not account for the roleof sympathetic activity. Because risk in the LQT1
variant has been associated with exercise and other
forms of sympathetic stimulation, it was intuitive
that increased sympathetic activity should be asso-
ciated with higher risk. Accordingly, the investigators
looked at noninvasive surrogates for sympathetic
activity and paradoxically observed that SMCs
demonstrated less QT variability in the low-frequency
range compared with AMCs. Thus, greater sympa-
thetic activity and less parasympathetic activity
appear protective in this population, in contrast to
other disease states. This unique observation raises
questions about our concepts of pathophysiology for
LQT1 and holds implications for risk proﬁling, at least
for carriers of A341V.
One must remain cautious, however, about 3
possibilities. The ﬁrst is whether the previously
described protective effect of parasympathetic activ-
ity, even if reduced, overrides a potentially adverse
effect of increased sympathetic drive, giving the
appearance of sympathetic protection. This contrasts
with sympathetic drive being uniquely protective.
This study’s design does not permit this distinc-
tion, although the QT parameter used suggests
independence.
The second concern focuses on whether the nature
of this speciﬁc mutation allows generalization to
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377other variants of LQT1 or other LQT subsets. Because
A341V is properly characterized as a “hot spot,” with
extraordinarily high event rates, one wonders
whether the negative association between clinical
events and increased sympathetic activity might be
unique to this population. Further studies that
include other variants associated with LQT1, and
possibly A341V from non–South African subjects, as
was done in prior parasympathetic studies, are
needed to determine whether this is a general
association.
The third point relates to the notion that the
sympathetic responses observed in this population
are genetically driven. The possibilities that genetic
variants affecting autonomic nervous system ex-
pression interact in a complex pathway with the LQT
myocardial line, or conversely that another variant
alters ion channel response to sympathetic stimula-
tion, are considerations of interest. These remain
hypothetical because the researchers have not yet
identiﬁed genetic variants associated with the
observed autonomic response. A rationale for their
concept comes from previous studies suggesting thatboth carriers and noncarriers of A341V had similar
wide distributions of baroreﬂex sensitivity (12), inti-
mating that the pattern of parasympathetic respon-
siveness is genetically driven, even though the
distribution of responses are continuous, rather than
dichotomous (9). Nonetheless, if such variants are
identiﬁed, they could contribute to better risk
proﬁling among A341V carriers, and perhaps other
variants. Stated another way, there appear to be
modiﬁer genes affecting a physiological pathway
generally known to be associated with risk in LQTS, in
which the response to the autonomic stimulus is
modiﬁed by a separate genetic inﬂuence. This pro-
vides a reasonable direction for future studies,
focusing on individual risk prediction by modiﬁcation
genetics targeting expression of inﬂuences external
to the primary QT defect.
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